X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
https://www.fiercebiotech.com/biotech/lilly-pfizer-stop-development-osteoarthritis-drug-after-fda-rejection-extending-bleak-run
https://www.prnewswire.com/news-releases/lilly-reports-robust-third-quarter-2021-financial-results-as-pipeline-success-strengthens-future-growth-potential-301408065.html
https://www.raps.org/news-and-articles/news-articles/2021/9/euro-roundup-chmp-recommends-drugs-from-biogen-and
https://investor.lilly.com/news-releases/news-release-details/us-fda-accepts-regulatory-submission-tanezumab-potential-first
https://www.fiercepharma.com/pharma/amid-important-launches-lilly-s-bio-medicines-head-shaw-steps-aside
https://www.biopharmadive.com/news/safety-setback-for-pfizer-lilly-pain-drug-should-have-regeneron-and-teva-f/553164/
https://www.reuters.com/article/us-pfizer-study/lower-dose-of-pfizer-lilly-painkiller-misses-main-goals-in-late-stage-study-idUSKCN1RU2J4?feedType=RSS&feedName=healthNews
https://www.businesswire.com/news/home/20190418005771/en/Pfizer-Lilly-Announce-Top-Line-Results-Long-Term-Phase
Market Place
Share 
